Abstract:Background: Ketamine, an arylcyclohexylamine dissociative anesthetic agent, has evolved into a versatile therapeutic. It has a rapid-onset, well-understood cardiovascular effects and a favorable safety profile in clinical use. Its enantiomeric compound, esketamine, was approved by the Food and Drug Administration in 2019 for both treatment-resistant depression and major depressive disorder with suicidal ideation. Areas of Uncertainty: Research indicates dose-dependent impacts on cognition, particularly affecting episodic and working memory following both acute administration and chronic use, albeit temporarily for the former and potentially persistent for the latter. Alongside acute risks to cardiovascular stability, ketamine use poses potential liver toxicity concerns, especially with prolonged or repeated exposure within short time frames. The drug's association with "ketamine cystitis," characterized by bladder inflammation, adds to its profile of physiological risks. Therapeutic Advances: Data demonstrate a single intravenous infusion of ketamine exhibits antidepressant effects within hours (weighted effect size averages of depression scores (N = 518) following a single 0.5 mg/kg infusion of ketamine is d = 0.96 at 24 hours). Ketamine is also effective at reducing posttraumatic stress disorder (PTSD) symptom severity following repeated infusions (Clinician-Administered PTSD Scale scores: −11.88 points compared with midazolam control). Ketamine also decreased suicidal ideation in emergency settings (Scale for Suicidal Ideation scores: −4.96 compared with midazolam control). Through its opioid-sparing effect, ketamine has revolutionized postoperative pain management by reducing analgesic consumption and enhancing recovery. Limitations: Many studies indicate that ketamine's therapeutic effects may subside within weeks. Repeated administrations, given multiple times per week, are often required to sustain decreases in suicidality and depressive symptoms. Conclusions: Ketamine's comprehensive clinical profile, combined with its robust effects on depression, suicidal ideation, PTSD, chronic pain, and other psychiatric conditions, positions it as a substantial contender for transformative therapeutic application.

Psychedelic Therapy: A Primer for Primary Care Clinicians—Historical Perspective and Overview

Psychedelic Therapy: A Primer for Primary Care Clinicians—The Strengths, Weaknesses, Opportunities, and Threats of Psychedelic Therapeutics

Psychedelic Therapy: A Primer for Primary Care Clinicians—Lysergic Acid Diethylamide (LSD)

Psychedelic Therapy: A Primer for Primary Care Clinicians—Psilocybin

Decision-Making around Psychedelics for Depression and Anxiety: a Model Based on Online Discussions

Psychedelic Therapy: A Primer for Primary Care Clinicians—Ibogaine

Psychedelic therapy in depression and substance use disorders

Psychedelic research at a crossroads

Psychedelics and Other Psychoplastogens for Treating Mental Illness

The cyclical revival of psychedelics in psychiatric treatment

Psychedelic Therapy: A Primer for Primary Care Clinicians—N,N-Dimethyltryptamine and Ayahuasca

Psychedelic Therapy: A Primer for Primary Care Clinicians—Ketamine

Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders

New Paradigms of Old Psychedelics in Schizophrenia

Psychedelic-Assisted Therapy and Psychedelic Science: A Review and Perspective on Opportunities in Neurosurgery and Neuro-Oncology

The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology

Beyond psychedelics: set and setting in general psychiatric practice

Psychedelics and Consciousness: Expanding the Horizons of Mind and Therapy

Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine

The Psychedelic Future of Post-Traumatic Stress Disorder Treatment

Psilocybin, moralization and psychotherapy: a coping review and a case report